News
The first participant has been dosed in a Phase 1 trial testing F230 for the treatment of pulmonary arterial hypertension.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback